ArticleArthritis research & therapy2026
Early risk stratification in lupus nephritis based on established prognostic factors: association with outcomes under triple therapy.
Article in Arthritis research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo apply the 2025 EULAR prognostic factors to identify subgroups of patients with lupus nephritis (LN) in which triple therapy was associated with higher complete renal response (CR) rates.
methodsWe conducted a medical record review of patients with biopsy-proven class III, IV, or V LN who were treated at our hospital between 2000 and 2024. Multivariate logistic regression was used to identify EULAR 2025 prognostic factors independently associated with CR. Patients were stratified according to major prognostic factors and the cumulative burden of additional factors. Cumulative CR rates were compared, and Cox proportional hazards models were applied to evaluate the association between risk stratification and CR.
resultsAmong the 170 patients included in this study, nephrotic-range proteinuria and a history of previous LN flare were negatively associated with CR (odds ratio [OR] 0.25, 95% confidence interval [CI] 0.11-0.55, p < 0.01 and OR 0.29, 95% CI 0.12-0.65, p < 0.01, respectively). Using a stepwise risk stratification approach incorporating these factors and the cumulative number of remaining prognostic factors, patients were classified into low-, moderate-, and high-risk groups, showing a clear gradient in CR rates (94.0% vs. 71.8% vs. 40.9%, respectively, p < 0.01). Using the high-risk group as the reference, the likelihood of achieving CR was substantially higher in the low- and moderate-risk groups (hazard ratio [HR] 22.8, 95% CI 8.27-81.24, p < 0.01 and HR 3.7, 95% CI 1.53-9.52, p = 0.01). In the high-risk group, triple therapy remained independently associated with CR (adjusted HR 3.13, 95% CI 1.17-8.73, p = 0.02).
conclusionsThese findings suggest that baseline risk stratification identified subgroups in which triple therapy was associated with higher CR rates. Prospective validation in independent cohorts is required before this approach can inform treatment selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.